31.70
price up icon3.36%   1.035
 
loading
Genmab Adr stock is traded at $31.70, with a volume of 2.00M. It is up +3.36% in the last 24 hours and up +27.46% over the past month. Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$30.67
Open:
$30.8
24h Volume:
2.00M
Relative Volume:
1.44
Market Cap:
$20.34B
Revenue:
$2.62B
Net Income/Loss:
$966.70M
P/E Ratio:
21.13
EPS:
1.5004
Net Cash Flow:
$1.09B
1W Performance:
+7.64%
1M Performance:
+27.46%
6M Performance:
+69.88%
1Y Performance:
+31.26%
1-Day Range:
Value
$30.74
$31.71
1-Week Range:
Value
$28.36
$31.70
52-Week Range:
Value
$17.23
$31.70

Genmab Adr Stock (GMAB) Company Profile

Name
Name
Genmab Adr
Name
Phone
-
Name
Address
-
Name
Employee
2,639
Name
Twitter
@Genmab
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
GMAB's Discussions on Twitter

Compare GMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GMAB
Genmab Adr
31.71 18.88B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
403.35 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.50 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.85 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
773.50 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
343.61 37.42B 3.81B -644.79M -669.77M -6.24

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-23-25 Upgrade Guggenheim Neutral → Buy
Apr-01-25 Downgrade Bernstein Mkt Perform → Underperform
Mar-11-25 Upgrade William Blair Mkt Perform → Outperform
Feb-13-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-04-24 Resumed Morgan Stanley Equal-Weight
Aug-20-24 Downgrade JP Morgan Overweight → Neutral
Jul-15-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab Adr Stock (GMAB) Latest News

pulisher
03:28 AM

Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World

03:28 AM
pulisher
Sep 30, 2025

TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Sep 30, 2025
pulisher
Sep 29, 2025

Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga

Sep 29, 2025
pulisher
Sep 29, 2025

European Stocks Higher to Kick Off the Week - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World

Sep 29, 2025
pulisher
Sep 29, 2025

Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se

Sep 29, 2025
pulisher
Sep 25, 2025

Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 25, 2025
pulisher
Sep 24, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade - Defense World

Sep 24, 2025
pulisher
Sep 23, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst Upgrade - MarketBeat

Sep 23, 2025
pulisher
Sep 16, 2025

Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 16, 2025
pulisher
Sep 15, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Sep 15, 2025
pulisher
Sep 15, 2025

Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 15, 2025
pulisher
Sep 14, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat

Sep 14, 2025
pulisher
Sep 10, 2025

Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 10, 2025
pulisher
Sep 09, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 08, 2025
pulisher
Sep 05, 2025

Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 05, 2025
pulisher
Sep 04, 2025

Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 04, 2025
pulisher
Sep 03, 2025

Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 03, 2025
pulisher
Sep 02, 2025

Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 02, 2025
pulisher
Sep 01, 2025

Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 01, 2025
pulisher
Aug 27, 2025

Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World

Aug 27, 2025
pulisher
Aug 27, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Aug 27, 2025
pulisher
Aug 22, 2025

Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World

Aug 22, 2025
pulisher
Aug 21, 2025

IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl

Aug 21, 2025
pulisher
Aug 20, 2025

IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily

Aug 20, 2025
pulisher
Aug 19, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 19, 2025
pulisher
Aug 19, 2025

IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl

Aug 19, 2025
pulisher
Aug 18, 2025

What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl

Aug 18, 2025
pulisher
Aug 15, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World

Aug 15, 2025
pulisher
Aug 11, 2025

What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World

Aug 11, 2025
pulisher
Aug 09, 2025

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

Aug 07, 2025

Genmab Adr Stock (GMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$86.39
price up icon 1.86%
$101.83
price up icon 3.29%
$36.17
price up icon 2.51%
$146.86
price up icon 2.04%
biotechnology ONC
$343.76
price up icon 0.79%
Cap:     |  Volume (24h):